Effects of perioperative intraperitoneal chemotherapy with 5-fluorouracil sustained release agent on advanced gastric cancer
- VernacularTitle:术中腹腔内5-氟尿嘧啶缓释化疗对进展期胃癌的疗效
- Author:
Peiyu LI
;
Na LIU
;
Rong LI
;
Yong ZHANG
- Publication Type:Journal Article
- Keywords:
Gastric cancer;
5-fluorouracil;
Regional chemotherapy
- From:
Chinese Journal of Digestive Surgery
2008;7(5):349-350
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effects of perioperative intraperitoneal chemotherapy with 5-fluorouracil (5-FU) sustained release agent on the local recurrence and survival rates of patients with advanced gastric cancer. Methods The clinical data of 100 patients with advanced gastric cancer who had been admitted to our hospital from January 2002 to December 2004 were retrospectively analyzed. All patients were divided into treatment group and control group. Only patients in the treatment group were implanted with 5-FU sustained release agent (800 mg) in abdominal cavity after D2 gastrectomy. All patients accepted chemotherapy according to the FOLFOX regimen. Results The 3-year survival rate and 3-year disease free survival rate were 45% and 28% for treatment group, which were significantly higher than 32% and 16% for control group. Conclusions Intraperi-toneal implantation of 5-FU sustained release agent during operation can decrease local recurrence rate and improve the 3-year survival rate of patients with advanced gastric cancer after radical gastrectomy.
